An oncologist who often interviews medical school candidates reflects on the qualities that make a good doctor. (ASCO Connection)
Using a type of artificial intelligence, researchers at Johns Hopkins found that cancers cells with a greater number and variety of receptors seem to be more responsive to treatment.
As part of the Choosing Wisely campaign for 2018, the American Society of Breast Surgeons announced five clinical practices that clinicians and patients should consider avoiding.
Results of a new study honed the components of a Mediterranean diet that offer the most protection against prostate cancer. (Journal of Urology)
Editors of Rehabilitation Oncology devoted an entire issue to discussion of lymphedema.
A German agency that evaluates new drugs has called for head-to-head comparative studies of immunotherapies. (Reuters)
New insights into why pregnancy seems to protect women against melanoma and improve response to immune checkpoint inhibitors. (University of Pennsylvania, eLife)
The FDA required a Health Care Provider Letter urging vigilance in monitoring patients for anaphylactic reactions to rolapitant (Varubi), a drug used to prevent chemotherapy-induced nausea and vomiting.
On the basis of updated data from a phase III trial, the FDA has extended the indication for carfilzomib (Kyprolis) and dexamethasone to include improved mortality in multiple myeloma. (Amgen)
The FDA also OK’d a first-in-human trial of a vaccine treatment for metastatic colorectal cancer. (Treos Bio)
The American Society of Clinical Oncology and the American Society for Radiation Oncology have established a registry to track and improve the quality of cancer care.
Researchers at the University of Texas Southwestern Medical Center in Dallas have begun testing a nanoparticle-based technology that lights up tumors, making the cancers easier to find and evaluate.
More evidence that depression may worsen outcomes in cancer, this time head and neck cancer. (Cancer)